Simmons Bank Has $7.20 Million Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Simmons Bank lowered its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.3% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 14,645 shares of the medical equipment provider’s stock after selling 50 shares during the quarter. Simmons Bank’s holdings in Intuitive Surgical were worth $7,195,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in ISRG. Mirador Capital Partners LP increased its position in Intuitive Surgical by 1.4% in the 3rd quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider’s stock valued at $1,732,000 after acquiring an additional 50 shares during the period. Advisors Asset Management Inc. raised its position in Intuitive Surgical by 18.1% during the 1st quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock worth $2,945,000 after purchasing an additional 1,129 shares during the last quarter. Consolidated Planning Corp lifted its holdings in Intuitive Surgical by 17.4% during the 3rd quarter. Consolidated Planning Corp now owns 8,099 shares of the medical equipment provider’s stock worth $3,979,000 after buying an additional 1,198 shares during the period. Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of Intuitive Surgical by 617.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider’s stock valued at $39,622,000 after buying an additional 76,649 shares during the last quarter. Finally, Brookstone Capital Management increased its stake in shares of Intuitive Surgical by 22.4% in the second quarter. Brookstone Capital Management now owns 12,530 shares of the medical equipment provider’s stock valued at $5,340,000 after buying an additional 2,289 shares during the period. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of ISRG opened at $537.07 on Wednesday. The firm has a market capitalization of $191.29 billion, a P/E ratio of 86.35, a P/E/G ratio of 5.27 and a beta of 1.39. Intuitive Surgical, Inc. has a 52 week low of $281.12 and a 52 week high of $542.59. The stock has a 50 day moving average price of $495.85 and a two-hundred day moving average price of $455.08.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.24 by $0.32. The business had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.01 billion. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. On average, equities analysts forecast that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current year.

Analyst Ratings Changes

ISRG has been the topic of several analyst reports. Mizuho upped their target price on Intuitive Surgical from $440.00 to $500.00 in a report on Thursday, October 17th. BTIG Research set a $535.00 price objective on shares of Intuitive Surgical in a research note on Friday, October 18th. Royal Bank of Canada lifted their target price on shares of Intuitive Surgical from $525.00 to $555.00 and gave the stock an “outperform” rating in a research note on Friday, October 18th. Barclays upped their price target on shares of Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research report on Thursday, July 18th. Finally, The Goldman Sachs Group set a $604.00 price objective on Intuitive Surgical in a research report on Friday, October 18th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus price target of $513.74.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, insider Jamie Samath sold 269 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $539.89, for a total value of $145,230.41. Following the completion of the sale, the insider now owns 8,757 shares in the company, valued at approximately $4,727,816.73. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now owns 3,001 shares in the company, valued at approximately $1,461,006.84. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jamie Samath sold 269 shares of Intuitive Surgical stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $539.89, for a total transaction of $145,230.41. Following the completion of the sale, the insider now directly owns 8,757 shares in the company, valued at approximately $4,727,816.73. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 91,178 shares of company stock valued at $45,897,071 over the last ninety days. Corporate insiders own 0.80% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.